nach oben

Breast Cancer Research and Treatment

Erschienen in:

01.12.2011 | Epidemiology

Serum CD44 levels and overall survival in patients with HER2-positive breast cancer

verfasst von: Jong-Min Baek, Quanri Jin, Joe Ensor, Delphine R. Boulbes, Francisco J. Esteva

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Abstract

CD44 is an adhesion molecule involved in tumor cell invasion and metastasis. The function of CD44 in breast cancer is not understood completely, or is its role as a predictive or prognostic factor. In this study, we tested for the hypothesis that the concentration of soluble CD44 (sCD44) in serum is correlated with clinicopathological factors, especially HER2, and survival in patients with breast cancer. We retrospectively identified 110 patients with breast cancer who had been treated at The University of Texas MD Anderson Cancer Center (MDACC) from September 2001 to May 2004. Sera were collected before definitive surgery in patients with stage I or II breast cancer, before initiation of neoadjuvant chemotherapy (if indicated) for patients with stage I–III breast cancer, and before initiation of systemic therapy in patients with stage IV breast cancer. sCD44 levels were determined using an enzyme-linked immunosorbent assay. The median age at diagnosis was 51 years (range, 28.6–87.1 years). sCD44 concentration was correlated with tumor stage (P = 0.0308). sCD44 serum concentration did not predict pathological response in patients treated with neoadjuvant chemotherapy. Among patients with distant metastases, sCD44 levels were significantly higher in patients with liver involvement than in patients with metastases at other sites. The overall survival rate did not differ between patients with high sCD44 concentration and patients with low sCD44 concentration. However, sCD44 concentration was a significant predictor of overall survival for patients with HER2-positive breast cancer, while no difference in overall survival rates was observed in patients with HER2-negative breast cancer. To the best of our knowledge, this is the first study to show an association between circulating sCD44 levels and survival in HER2-positive breast cancer patients. Our results suggest a role for sCD44 as a prognostic marker. Furthermore, sCD44 level may offer a new clinical therapeutic target in HER2-positive breast cancer.

Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100:3983–3988PubMedCrossRef

Stamenkovic I, Aruffo A, Amiot M, Seed B (1991) The hematopoietic and epithelial forms of CD44 are distinct polypeptides with different adhesion potentials for hyaluronate-bearing cells. EMBO J 10:343–348PubMed

Nagano O, Saya H (2004) Mechanism and biological significance of CD44 cleavage. Cancer Sci 95:930–935PubMedCrossRef

Okamoto I, Tsuiki H, Kenyon LC et al (2002) Proteolytic cleavage of the CD44 adhesion molecule in multiple human tumors. Am J Pathol 160:441–447PubMedCrossRef

Guo YJ, Liu G, Wang X et al (1994) Potential use of soluble CD44 in serum as indicator of tumor burden and metastasis in patients with gastric or colon cancer. Cancer Res 54:422–426PubMed

Lackner C, Moser R, Bauernhofer T et al (1998) Soluble CD44 v5 and v6 in serum of patients with breast cancer. Correlation with expression of CD44 v5 and v6 variants in primary tumors and location of distant metastasis. Breast Cancer Res Treat 47:29–40PubMedCrossRef

Molica S, Vitelli G, Levato D, Giannarelli D, Gandolfo GM (2001) Elevated serum levels of soluble CD44 can identify a subgroup of patients with early B-cell chronic lymphocytic leukemia who are at high risk of disease progression. Cancer 92:713–719PubMedCrossRef

Niitsu N, Iijima K (2002) High serum soluble CD44 is correlated with a poor outcome of aggressive non-Hodgkin’s lymphoma. Leuk Res 26:241–248PubMedCrossRef

Guriec N, Marcellin L, Gairard B et al (1996) CD44 exon 6 expression as a possible early prognostic factor in primary node negative breast carcinoma. Clin Exp Metastasis 14:434–439PubMedCrossRef

10.

Lockhart MS, Waldner C, Mongini C et al (1999) Evaluation of soluble CD44 in patients with breast and colorectal carcinomas and non-Hodgkin’s lymphoma. Oncol Rep 6:1129–1133PubMed

11.

Sanchez Lockhart M, Hajos SE, Basilio FM, Mongini C, Alvarez E (2001) Splice variant expression of CD44 in patients with breast and ovarian cancer. Oncol Rep 8:145–151PubMed

12.

Mayer S, zur Hausen A, Watermann DO et al (2008) Increased soluble CD44 concentrations are associated with larger tumor size and lymph node metastasis in breast cancer patients. J Cancer Res Clin Oncol 134:1229–1235PubMedCrossRef

13.

Sheen-Chen SM, Chen WJ, Eng HL, Sheen CC, Chou FF, Cheng YF (1999) Evaluation of the prognostic value of serum soluble CD 44 in patients with breast cancer. Cancer Invest 17:581–585PubMedCrossRef

14.

Amirghofran Z, Jalali SA, Hosseini SV, Vasei M, Sabayan B, Ghaderi A (2008) Evaluation of CD44 and CD44v6 in colorectal carcinoma patients: soluble forms in relation to tumor tissue expression and metastasis. J Gastrointest Cancer 39:73–78PubMedCrossRef

15.

Woodman AC, Sugiyama M, Yoshida K et al (1996) Analysis of anomalous CD44 gene expression in human breast, bladder, and colon cancer and correlation of observed mRNA and protein isoforms. Am J Pathol 149:1519–1530PubMed

16.

Bhatavdekar JM, Patel DD, Shah NG et al (2000) Prognostic significance of immunohistochemically localized biomarkers in stage II and stage III breast cancer: a multivariate analysis. Ann Surg Oncol 7:305–311PubMedCrossRef

17.

Yamane N, Tsujitani S, Makino M, Maeta M, Kaibara N (1999) Soluble CD44 variant 6 as a prognostic indicator in patients with colorectal cancer. Oncology 56:232–238PubMedCrossRef

18.

Kokko LL, Hurme S, Maula SM et al (2011) Significance of site-specific prognosis of cancer stem cell marker CD44 in head and neck squamous-cell carcinoma. Oral Oncol 47(6):510–516PubMedCrossRef

19.

Esteva FJ, Hortobagyi GN, Sahin AA, Smith TL, Chin DM, Liang SY, Pusztai L, Buzdar AU, Bacus SS (2001) Expression of erbB/HER receptors, heregulin and P38 in primary breast cancer using quantitative immunohistochemistry. Pathol Oncol Res 7(3):171–177

20.

Korkaya H, Paulson A, Iovino F, Wicha MS (2008) HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene 27:6120–6130PubMedCrossRef

21.

Li X, Lewis MT, Huang J et al (2008) Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 100:672–679PubMedCrossRef

22.

McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2006) REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 100:229–235PubMedCrossRef

23.

Gunthert U, Hofmann M, Rudy W et al (1991) A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 65:13–24PubMedCrossRef

24.

Seiter S, Arch R, Reber S et al (1993) Prevention of tumor metastasis formation by anti-variant CD44. J Exp Med 177:443–455PubMedCrossRef

25.

Masson D, Denis MG, Denis M et al (1999) Soluble CD44: quantification and molecular repartition in plasma of patients with colorectal cancer. Br J Cancer 80:1995–2000PubMedCrossRef

26.

Kopp R, Classen S, Wolf H, Gholam P, Possinger K, Wilmanns W (2001) Predictive relevance of soluble CD44v6 serum levels for the responsiveness to second line hormone- or chemotherapy in patients with metastatic breast cancer. Anticancer Res 21:2995–3000PubMed

27.

Zhou J, Nagarkatti PS, Zhong Y, Creek K, Zhang J, Nagarkatti M (2010) Unique SNP in CD44 intron 1 and its role in breast cancer development. Anticancer Res 30:1263–1272PubMed

28.

Weg-Remers S, Hildebrandt U, Feifel G, Moser C, Zeitz M, Stallmach A (1998) Soluble CD44 and CD44v6 serum levels in patients with colorectal cancer are independent of tumor stage and tissue expression of CD44v6. Am J Gastroenterol 93:790–794PubMedCrossRef

29.

Zalewski B (2004) Levels of v5 and v6 CD44 splice variants in serum of patients with colorectal cancer are not correlated with pT stage, histopathological grade of malignancy and clinical features. World J Gastroenterol 10:583–585PubMed

30.

Gotte M, Yip GW (2006) Heparanase, hyaluronan, and CD44 in cancers: a breast carcinoma perspective. Cancer Res 66:10233–10237PubMedCrossRef

31.

Chang SM, Xing RD, Zhang FM, Duan YQ (2009) Serum soluble CD44v6 levels in patients with oral and maxillofacial malignancy. Oral Dis 15:570–572PubMedCrossRef

32.

Kim HJ, Kim MJ, Ahn SH et al (2011) Different prognostic significance of CD24 and CD44 expression in breast cancer according to hormone receptor status. Breast 20:78–85PubMedCrossRef

33.

Saito H, Tsujitani S, Katano K, Ikeguchi M, Maeta M, Kaibara N (1998) Serum concentration of CD44 variant 6 and its relation to prognosis in patients with gastric carcinoma. Cancer 83:1094–1101PubMedCrossRef

34.

Klingbeil P, Natrajan R, Everitt G et al (2010) CD44 is overexpressed in basal-like breast cancers but is not a driver of 11p13 amplification. Breast Cancer Res Treat 120:95–109PubMedCrossRef

35.

Shah NG, Trivedi TI, Vora HH et al (2010) CD44v6 expression in primary breast carcinoma in western India: a pilot clinicopathologic study. Tumori 96:971–977PubMed

36.

Berner HS, Suo Z, Risberg B, Villman K, Karlsson MG, Nesland JM (2003) Clinicopathological associations of CD44 mRNA and protein expression in primary breast carcinomas. Histopathology 42:546–554PubMedCrossRef

Titel: Serum CD44 levels and overall survival in patients with HER2-positive breast cancer
verfasst von: Jong-Min Baek
Quanri Jin
Joe Ensor
Delphine R. Boulbes
Francisco J. Esteva
Publikationsdatum: 01.12.2011
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 3/2011
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-011-1691-z

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Serum CD44 levels and overall survival in patients with HER2-positive breast cancer

Abstract

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2011

Genetic predictors of taxane-induced neurotoxicity in a SWOG phase III intergroup adjuvant breast cancer treatment trial (S0221)

Molecular detection of breast cancer metastasis in sentinel lymph nodes by reverse transcriptase polymerase chain reaction (RT-PCR): identifying, evaluating and establishing multi-marker panels

Combined effects of MDM2 SNP309 and TP53 R72P polymorphisms, and soy isoflavones on breast cancer risk among Chinese women in Singapore

The effect of delays in treatment for breast cancer metastasis on survival

β-Adrenergic receptors (β-AR) regulate VEGF and IL-6 production by divergent pathways in high β-AR-expressing breast cancer cell lines

Single nucleotide polymorphisms in the 20q13 amplicon genes in relation to breast cancer risk and clinical outcome

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie